Outcome after azacitidine treatment in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia in the Clinic of Hematology at St. Marina University Hospital, Varna by Micheva, Ilina et al.
Scripta Scientica Medica, 2018;50(1):31-35
Medical University of Varna
31
ORIGINAL ARTICLES
OUTCOME AFTER AZACITIDINE TREATMENT  
IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC 
SYNDROME AND ACUTE MYELOID LEUKEMIA  
IN THE CLINIC OF HEMATOLOGY  
AT ST. MARINA UNIVERSITY HOSPITAL, VARNA
Ilina Micheva1,2, Vladimir Gerov1,2, Stela Dimitrova1,2, Merlin Efraim1,2, Liana Gercheva1,2
1Department of Internal Diseases, Faculty of Medicine, Medical University of Varna 
2Clinic of Hematology, St. Marina University Hospital, Varna
Address for correspondence:  
Ilina Micheva
Clinic of Hematology
St. Marina University Hospital
1 Hr. Smirnenski Blvd
9000 Varna
e-mail: ilinamicheva@gmail.com
Received: February 18, 2018
Accepted: March 26, 2018
ABSTRACT
INTRODUCTION: Hypomethylating agents have become a standard therapy for high-risk myelodysplas-
tic syndromes (MDS) and elderly patients with acute myeloid leukemia (AML).
AIM: The aim of the study was to assess the efficacy of azacitidine treatment in patients with MDS and AML 
followed for 18 months.
MATERIALS AND METHODS: Twenty-seven patients with MDS and AML treated in the Clinic of He-
matology at St. Marina University Hospital, Varna were included in the study. Azacitidine was administered 
subcutaneously at a dose of 75 mg/m2 for 7 days. Disease assessment was performed on  the 3rd month, 6th 
month, and at progression.
RESULTS: Twenty-seven patients were analyzed. Their median age was 71.5 years. Nine had refractory ane-
mia with excess of blasts II (RAEB II), 5 had chronic myelomonocytic leukemia II (CMML II), 1 was with 
unclassifiable MDS (MDS-U), and 12 with AML. The median number of administered cycles was 6 (1-19). 
Eleven patients completed 6 cycles of azacitidine. Partial response was achieved in 9 patients (33%) (7 MDS 
and 2 AML), stable disease in 8 (29%) (5 MDS and 3 AML). Progressive disease was observed in 10 patients 
(37%). The response correlated with the type of the disease (p=0.03), cytogenetic risk (p=0.01), and survival 
(p=0.000). At 18 months, 60% of MDS patients were alive compared to 41.7% in the AML group. The medi-
an time to death in the AML patient group was 2.5 months. The mean overall survival was 10.4 months (12.6 
months for MDS patients and 5.4 months for AML patients).
CONCLUSION: The therapy with azacitidine is an option for elderly patients with high-risk MDS. In pa-
tients with AML a rapid progression is observed during the first two cycles with mortality rate of 58.3%. Scr 
Sci Med. 2018;50(1):31-35
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Hematology, St. Marina University Hospital, Var-
na were included in the study. Patients were eligi-
ble for azacitidine treatment if they were with high-
risk MDS, determined by the revised internation-
al prognostic scoring system (IPSS-R) (6), CMML II 
and AML, aged 65 years or older, not eligible for in-
tensive chemotherapy and hematopoietic stem cell 
transplantation. Azacitidine was administered sub-
cutaneously in a standard dose of 75mg/m2 per day 
for 7 days, every 28 days. Blood counts were done 
monthly. Disease assessment was performed on the 
3rd and the 6th month after initiation of the treatment, 
or at progression. Response was evaluated according 
to the International Working Group (IWG) response 
criteria in myelodysplasia (7). Mean survival was esti-
mated by the Kaplan-Meier method. For evaluation 
of linear relationships, a two-tailed Pearson Corre-
lation test was used. Correlation was considered sig-
nificant at the 0.05 level. Statistical analysis was per-
formed using SPSS 19.
RESULTS
Between June 2016 and December 2017, 27 pa-
tients were treated with azacitidine. According to the 
WHO classification 9 patients were with refracto-
ry anemia with excess of blasts II (RAEB II), 5 with 
CMML II, 1 with MDS unclassifiable (MDS-U) and 
12 with AML. Median age was 71.5 years (range 44-
80) and 70.3% of the patients were over 65 years. Ac-
cording to IPSS-R 2 MDS patients were scored as 
very high risk, 1 as high, and 5 as intermediate (Fig. 
1a). Four of the AML patients were high and 8 - in-
termediate risk (Fig.1b). According to cytogenetics 16 
patients were with normal karyotype, 6 with com-
plex, and 5 patients were with other cytogenetic ab-
normalities [46, XY, del (7) (n=2), 46, XY, add(16q) 
(n=1), 47, XY, +19 (n=1), 47, XY, +C (n=1)]. In 23 pa-
tients the treatment with azacitidine was first-line 
chemotherapy. In 3 patients with AML, azacitidine 
was initiated after failure of 7+3 or low doses Ara-C, 
1 patient with CMMLII was previously treated with 
hydroxyurea. 
Azacitidine was given for a median of six cy-
cles (1-19). The median azacitidine cycle length was 
28 days. Seventeen patients completed three cycles of 
treatment, 11 patients - six cycles. Disease assessment 
was performed on the 3rd and the 6th month after ini-
INTRODUCTION
DNA methylation is an important mechanism 
of epigenetic gene regulation. In human cells, DNA 
methylation occurs in cytosine residues that pre-
cede guanines (CpG) grouped in CpG-rich regions 
known as CpG islands. These islands are usually not 
methylated in normal cells. The methylation status 
of DNA is controlled by a family of DNA methyl-
transferases (DNMTs) (1). It is well known that com-
plex changes in DNA methylation are characteristic 
feature of many cancers; tumor suppressor genes can 
be silenced by aberrant hypermethylation (2). Hyper-
methylation is found in patients with myeloid malig-
nancies affecting hundreds of genes, involved in dif-
ferent signaling pathways. It has been shown that ab-
errant hypermethylation of genes is widespread in 
patients with myelodysplastic syndromes (MDS) and 
secondary acute myeloid leukemia (AML) (3). Hy-
permethylation increases with advanced disease and 
is a poor prognostic factor in MDS and AML. Pa-
tients with hypermethylation of at least one tumor 
suppressor gene have shorter survival (4).
This underlies the clinical efficacy of the hypo-
methylating agents for the treatment of patients with 
MDS and AML. Azacitidine is an analog of cytosine, 
where the carbon is replaced by nitrogen at the 5-po-
sition on the cytosine ring. DNMTs bind irrevers-
ibly to the cytosine analog but are unable to meth-
ylate it, which causes depletion of cellular DNMT 
levels. Azacitidine is integrated into both RNA and 
DNA, causing DNA hypomethylation and cytotoxic-
ity with DNA damage and inhibition of protein syn-
thesis (5).
Hypomethylating agents have become a stan-
dard therapy for high-risk MDS, chronic myelo-
monocytic leukemia II (CMML II) and elderly pa-
tients with AML who are not eligible for hematopoi-
etic stem cell transplantation.
AIM
The aim of the study was to assess the efficacy 
of azacitidine treatment in higher risk patients with 
MDS and AML. The clinical workup included re-
sponse assessment and survival.
MATERIALS AND METHODS
A group of 27 patients, 15 men and 12 wom-
en, with MDS and AML, treated in the Clinic of 
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tiation of the treatment, or at progression. The best 
response is presented on Fig. 2. 
Partial response (PR) was achieved in 9 patients 
(33%) (7 with MDS and 2 with AML). Eight patients 
(29%) had stable disease (SD) (5 with MDS and 3 
with AML). Ten patients (37%) had progressive dis-
ease (PD). The response correlated with the type of 
the disease (MDS or AML) (p=0.03), cytogenetic risk 
(p=0.01) and survival (p=0.000). AML transforma-
tion was observed in 3 patients with MDS (MDS-U, 
CMML II, and RAEB II) with time of transforma-
tion 3, 6, and 15 months, respectively. Hematologi-
cal improvement (HI) of hemoglobin was achieved 
in 5 patients and HI of platelets – in 9 patients (Fig. 3). 
All patients with HI became transfusion-inde-
pendent. The age had no influence on response and 
survival. At 18 months, on the basis of Kaplan-Meier 
estimates, 60% of all MDS patients were alive com-
pared with 41.7% in the AML group. All patients 
Fig. 1. Risk stratification in MDS (a) and AML patients (b)
Fig. 2. Response achieved during the treatment in MDS 
and AML patients
Fig. 3. Levels of hemoglobin (a) and platelets (b) measured prior to treatment, and on the 3rd and the 6th month
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died as a result of PD with a median time to death 
2.5 months. Mean Kaplan-Meier overall survival was 
10.4 months: 12.6 months for MDS patients and 5.4 
months for AML patients (Fig. 4). 
DISCUSSION
Myelodysplastic syndromes comprise a het-
erogeneous group of hematopoietic stem cell disor-
ders that differ by clinical phenotype and risk strati-
fication (8). Patients with high-risk MDS have inferi-
or survival and a high-risk for progression to AML. 
The median overall survival in very high and high-
risk MDS patients is 0.8 and 1.6 years, respectively 
(6). The therapeutic options in these risk groups are 
limited; no treatment strategies other than alloge-
neic stem-cell transplantation offer the potential to 
change the natural history of the disease (9). The first 
study of a Cancer and Leukemia Group B, compar-
ing treatment with azacitidine with best supportive 
care in high-risk MDS patients suggested improved 
overall survival with azacitidine (10). These results 
were confirmed by a large, prospective, randomized, 
phase III, clinical trial in which the median overall 
survival was 24.5 months for the azacitidine group 
versus 15.0 months for the conventional care group 
(11). 
AML is an aggressive malignancy with poor 
prognosis. Older patients with AML over 65 years of 
age, who are at greatest risk of developing AML, have 
particularly poor survival rates (12). Treatment op-
tions are limited because of a variety of adverse prog-
nostic risk factors, such as history of MDS, unfavor-
able karyotypes, poor performance status, and co-
morbidities. As a result, many older patients receive 
only palliative care. There is no universally accepted 
standard approach to treating AML in older patients. 
It was recently shown that azacitidine increases me-
dian overall survival by 3.8 months compared to cur-
rent commonly used AML treatments (13).
In our study, after 18 months of follow-up, 
60% of high-risk MDS patients were alive and con-
tinued their treatment. 46.6% of MDS patients have 
achieved PR and 26.6% remained in SD. Three pa-
tients died because of transformation into AML. 
Median survival is 12.6 months. In the AML pa-
tient group, 58.3% died within a median time of 2.5 
months. However, 5 out of the 12 patients with AML 
continued their treatment at the end of the 18-month 
follow-up - 2 with PR and 3 with SD. All patients 
with MDS and AML who achieved PR or SD showed 
improvement or stabilization of blood counts with 
reduction of the number of infectious complications 
and transfusions during azacitidine treatment. Pa-
tients with MDS achieved better response compared 
to AML and showed better survival rates. 
CONCLUSION
The therapy with azacitidine is an option for 
elderly patients with high-risk MDS. Patients with 
AML show rapid progression during the first two 
cycles of azacitidine with high mortality. This is the 
first study reporting results form azacitidine treat-
Fig. 4. Overall survival (a). Overall survival in MDS and AML (b)
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ment in Bulgaria. A larger cohort of patients and lon-
ger follow-up is required for further conclusions.
REFERENCES
1. Weber M, Hellmann I, Stadler MB, Ramos L, Pää-
bo S, Rebhan M, et al. Distribution, silencing po-
tential and evo- lutionary impact of promoter DNA 
meth- ylation in the human genome. Nat Genet. 
2007;39(4):457-66. doi: 10.1038/ng1990.
2. Esteller M. Epigenetics in cancer. N Engl J Med. 
2008;358(11):1148-59. doi: 10.1056/NEJMra072067.
3. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy 
TE, Paietta E, et al. MDS and secondary AML dis-
play unique patterns and abundance of aberrant 
DNA methylation. Blood. 2009;114(16):3448-58. 
doi: 10.1182/blood-2009-01-200519.
4. Aggerholm A, Holm MS, Guldberg P, Ole-
sen LH, Hokland P. Promoter hypermethyl-
ation of p15INK4B, HIC1, CDH1, and ER is fre-
quent in myelodysplastic syndrome and pre-
dicts poor prognosis in early-stage pa-
tients. Eur J Haematol. 2006;76(1):23-32. doi: 
10.1111/j.1600-0609.2005.00559.x.
5. Santini V, Melnick A, Maciejewski JP, Duprez 
E, Nervi C, Cocco L, et al. Epigenetics in focus: 
pathogenesis of myelodysplastic syndromes and 
the role of hypomethylating agents. Crit Rev On-
col Hematol. 2013;88(2):231-45. doi: 10.1016/j.
critrevonc.2013.06.004.
6. Greenberg PL, Tuechler H, Schanz J, Sanz G, Gar-
cia-Manero G, Solé F, et al. Revised international 
prognostic scoring system for myelodysplastic syn-
dromes. Blood. 2012;120(12):2454-65. doi: 10.1182/
blood-2012-03-420489.
7. Cheson BD, Greenberg P, Bennett JM, Lowenberg 
B, Wijermans PW, Nimer SD, et al. Clinical appli-
cation and proposal for modification of the Inter-
national Working Group (IWG) response criteria 
in myelodysplasia. Blood. 2006;108(2):419-25. doi: 
10.1182/blood-2005-10-4149.
8. Valent P, Horny HP, Bennett JM, Fonatsch C, 
Germing U, Greenberg P et al. Definitions and 
standards in the diagnosis and treatment of the my-
elodysplastic syndromes: consensus statements and 
report from a working conference. Leuk Res. 2007; 
31(6):727–36. doi: 10.1016/j.leukres.2006.11.009.
9. de Witte T, Suciu S, Verhoef G, Labar B, Archim-
baud E, Aul C, et al. Intensive chemotherapy fol-
lowed by allogeneic or autologous stem cell trans-
plantation for patients with myelodysplastic syn-
dromes (MDSs) and acute myeloid leukemia fol-
lowing MDS. Blood. 2001;98(8):2326-31.
10. Silverman LR, Demakos EP, Peterson BL, Kornblith 
AB, Holland JC, Odchimar-Reissig R, et al. Ran-
domized controlled trial of azacitidine in patients 
with the myelodysplastic syndrome: a study of the 
cancer and leukemia group B. J Clin Oncol. 2002; 
20(10):2429–40. doi: 10.1200/JCO.2002.04.117.
11. Fenaux P, Mufti GJ, Hellström-Lindberg E,  San-
tini V, Finelli C, Giagounidis A , et al. Efficacy of 
azacitidine compared with that of conventional 
care regimens in the treatment of higher-risk my-
elodysplastic syndromes: a randomised, open-label, 
phase III study. Lancet Oncol. 2009;10(3):223-32. 
doi: 10.1016/S1470-2045(09)70003-8.
12. Visser O, Trama A, Maynadi é M, Stiller C, Mar-
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